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Abstract
Background: Neoadjuvant chemotherapy has been considered the standard care in locally
advanced breast cancer. However, about 20% of the patients do not benefit from this clinical
treatment and, predictive factors of response were not defined yet. This study was designed to
evaluate the importance of biological markers to predict response and prognosis in stage II and III
breast cancer patients treated with taxane and anthracycline combination as neoadjuvant setting.
Methods: Sixty patients received preoperative docetaxel (75 mg/m2) in combination with
epirubicin (50 mg/m2) in i.v. infusion in D1 every 3 weeks after incisional biopsy. They received
adjuvant chemotherapy with CMF or FEC, attaining axillary status following definitive breast
surgery. Clinical and pathologic response rates were measured after preoperative therapy. We
evaluated the response rate to neoadjuvant chemotherapy and the prognostic significance of
clinicopathological and immunohistochemical parameters (ER, PR, p51, p21 and HER-2 protein
expression). The median patient age was 50.5 years with a median follow up time 48 months after
the time of diagnosis.
Results: Preoperative treatment achieved clinical response in 76.6% of patients and complete
pathologic response in 5%. The clinical, pathological and immunohistochemical parameters were
not able to predict response to therapy and, only HER2 protein overexpression was associated
with a decrease in disease free and overall survival (P = 0.0007 and P = 0.003) as shown by
multivariate analysis.
Conclusion: Immunohistochemical phenotypes were not able to predict response to neoadjuvant
chemotherapy. Clinical response is inversely correlated with a risk of death in patients submitted
to neoadjuvant chemotherapy and HER2 overexpression is the major prognostic factor in stage II
and III breast cancer patients treated with a neoadjuvant docetaxel and epirubicin combination.
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Background
Neoadjuvant or primary chemotherapy in large primary
breast cancer has been used with the purpose of reducing
tumor volume and promoting less aggressive surgery [1].
The disease's downstaging promotes higher conservative
breast surgery rates and [2], in patients with objective clin-
ical and pathological response, an increase in disease free
and overall survival rates has been observed [3,4]. Other-
wise, about 10% – 35% of the patients do not benefit
from this clinical approach [5,6]. The identification of this
group of patients could avoid the chemotherapy side
effects and point them toward other therapeutic alterna-
tives.
Clinical and pathological criteria neither predict response
to neoadjuvant chemotherapy nor accurately define
tumor biology. Tumors with the same histological type,
grade and clinical staging behave differently [7]. The cur-
rent hypothesis is that morphologically similar tumors
have distinct gene expression with distinct phenotypic
profiles [8]. The development of new therapies directed at
specific molecular expression has lead researchers to eval-
uate the usefulness of tumor protein expression as predic-
tive factors of response.
Docetaxel, an agent that promotes microtubule stabiliza-
tion and prevents depolymerization, can cause cell cycle
arrest in the mitotic phase [9], and epirubicin, an anthra-
cycline that interacts with topoisomerase II and blocks
DNA transcription [10], have both currently been used in
adjuvant and neoadjuvant breast cancer treatment. In a
neoadjuvant setting, the combination of these two agents
is among the most actively described chemotherapy regi-
mens [11]. The study of the molecular tumor characteris-
tics and effects of the taxane and anthracycline
combination on protein modulation can provide infor-
mation about the mechanism of action and play an
important role in the individualization of neoadjuvant
therapy.
We evaluated the expression of p53, p21 and HER-2 pro-
tein expression by immunohistochemistry (IHC) before
and after neoadjuvant docetaxel plus epirubicin in locally
advanced breast cancer patients and their relationship
with clinical response and outcome.
Methods
Characteristics of patients and description of neoadjuvant 
therapy
Sixty women with a histological diagnosis of invasive
breast cancer in incisional biopsy specimens were
enrolled consecutively in the study. Inclusion criteria
included patients with locally advanced epithelial breast
cancer (AJCC clinical stage IIa, if T> 3 cm; IIb and III),
Karnofski performance status greater than 70% and age
under 75 years. From February 2000 to December 2002,
patients received treatment with taxane and anthracycline
(docetaxel 75 mg/m2 and epirubicin 50 mg/m2, i.v. infu-
sion, for one day every three weeks). No dose modifica-
tion was allowed. The median cycle of chemotherapy was
3 cycles (2 – 5) and the patients' median age was 50.5
years (29 – 68). Thirty-one patients were at stage II and
twenty-nine were at stage III. Presence of primary inflam-
matory breast carcinoma was an exclusion factor and
invasive ductal carcinoma was the most common histo-
logical type (82.7%). Sixteen tumors were grade I (23%)
and grade II and III was observed in 55.7% and 21.3% of
the tumors, respectively. The median follow up time was
48 months (24 – 69). Table 1 summarizes the patients'
characteristics.
None of these patients had distant metastasis nor had they
received prior therapy for cancer. Hepatic and renal func-
tion tests and blood cell count were carried out at each
chemotherapy cycle, and no toxicity greater than 1 or 2
was observed. Table 2 describes the toxicity effects due to
neoadjuvant chemotherapy. Chemotherapy was contin-
ued until tumors became operable in primary inoperable
lesions or until breast conserving surgery could be per-
formed in primary operable tumors. The patients with pri-
mary inoperable lesions who had no clinical response,
defined after at least two cycles of chemotherapy, were
subjected to a new incisional biopsy and given a second
line of treatment consisting of breast radiation therapy
(total dose of 50 Gy) combined with a CMF chemother-
apy regimen (cyclophosphamide 500 mg/m2, methotrex-
ate 50 mg/m2 and 5-fluoruracil 500 mg/m2 i.v. infusion,
for 1 day, each 21/21 days) before definitive breast sur-
gery. All procedures were carried out with the prior
informed consent of the patient.
Adjuvant treatment
Adjuvant chemotherapy was offered to all patients.
Regarding axillary lymph node status. The FEC regimen
(5-fluoruracil 500 mg/m2, epirubicin 50 mg/m2 and
cyclophosphamide 500 mg/m2 i.v. infusion, for 1 day,
each 21/21 days) was administered when more than three
positive axillary lymph nodes (ALN+) were present after
neoadjuvant treatment. The CMF regimen (cyclophospha-
mide 500 mg/m2, methotrexate 50 mg/m2 and 5-fluoru-
racil 500 mg/m2 i.v. infusion, for 1 day, each 21/21 days)
was used if there were three or less ALN+. All patients
received a total of nine chemotherapy cycles. Hormonal
adjuvant therapy was offered to all patients with estrogen
or progesterone receptor positive tumors. Patients
received tamoxifen at 20 mg PO for 60 months or until
disease recurrence.
Adjuvant radiotherapy was performed in the residual
breast parenchyma of all breast conserving surgery
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Table 2: Toxic effect incidences in sixty locally advanced breast cancer patients subjected to neoadjuvant docetaxel (75 mg/m2) and 
epirubicin (50 mg/m2) combination.
Toxicity (%)
Alopecia 100
Nausea and vomiting 19.2
Neutropenia 11.5
Febrile neutropenia 3.8
Fever 5.7
Diarrhea 5.7
Mucositis 3.8
Allergic reactions 3.8
Asthenia 1.9
Headache 1.9
Table 1: Characteristics of sixty breast cancer patients treated with neoadjuvant docetaxel plus epirubicin.
Characteristcs n = 60 (range) %
Age
Median 50 (29 – 67)
≤ 45 years 18 30
>45 years 42 70
Menopausal status
Pre 28 46.6
Post 32 53.4
Chemotherapy cycles (median) 3 (2 – 5)
Clinical Stage
IIA 12 20
IIB 19 31.7
IIIA 8 13.3
IIIB 18 30
IIIC 3 5
Histology
Ductal 49 81.7
Lobular 4 6.7
Medular 4 6.7
Outhers 3 5
Histologic grade
I 16 26.7
II 32 53.3
III 11 18.4
ER
Positive 45 75
Negative 15 25
PR
Positive 32 53.3
Negative 28 46.7
P53 protein
Positive 17 28.3
Negative 43 71.7
P21 protein
Positive 20 33.3
Negative 40 66.7
HER-2
Positive 11 18.3
Negative 49 81.7
N = number of patients; ER = estrogen receptor; PR = progesterone receptor.
BMC Cancer 2007, 7:36 http://www.biomedcentral.com/1471-2407/7/36
Page 4 of 10
(page number not for citation purposes)
patients (50 Gy). Patients who underwent mastectomy
received chest wall adjuvant radiotherapy if residual
tumors were five centimeters or greater (at the highest
pathological diameter) or if there was skin or muscle and
chest wall invasion (50 Gy). The supraclavicular fossa was
irradiated if there were four or more ALN+.
This study was approved by the local Ethics Committee in
accordance with the ethical guidelines of the 1975 Decla-
ration of Helsinki, revised 1983.
Assessment of response to neoadjuvant chemotherapy
The pathological and clinical assessment of response to
neoadjuvant chemotherapy was taken. All surgical speci-
mens from the definitive breast procedure were submitted
for pathological evaluation and were classified as having
a complete response (pCR) when no residual invasive car-
cinoma was seen.
The clinical stage and size of the primary tumor was
recorded before treatment. The measurement of the pri-
mary tumor consisted of the product of its greatest diam-
eter and its perpendicular diameter. The clinical response
was evaluated at each cycle of chemotherapy and prior to
definitive surgery on day 21 of the last cycle of chemother-
apy according to the product of primary tumor diameters
and the axillary clinical status, and was classified as a com-
plete response (CR), partial response (PR), stable disease
(SD), or progressive disease (PD) according to standard
UICC (International Union Against Cancer) criteria [12].
CR was defined as the disappearance of all clinical evi-
dence of the tumor including the axillary site; PR was
defined as a reduction of 50% or more in the sum of the
products of measured lesions or an estimated decrease in
tumor size of at least 50%, without the appearance of new
lesions. Clinical down staging in axillary status was neces-
sary; SD was defined as a decrease of less than 50% in the
sum of the products of measured lesions, or an estimated
decrease of less than 50% in lesion size or an increase of
less than 25%, without the appearance of new lesions.
Any measured or estimated increase greater than 25% or
the appearance of new lesions was defined as PD. No
change in clinical axillary status was classified as SD
regardless the change in primary tumor diameter. The
patients were classified into two groups: the objective
response group (OR), into which all patients classified as
CR or PR were placed, and the no response group (NR),
containing all patients classified as SD or PD.
Immunohistochemistry
All tissue samples had been routinely fixed in 4% neutral
formalin and embedded in paraffin. Briefly, 3-μm-thick
sections were cut from paraffin blocks containing repre-
sentative tumor samples. Paraffin sections were de-waxed
in xylene, rehydrated through a series of graded alcohols,
placed in 10 mM citrate buffer and submitted to heat
retrieval using a vapor lock for 40 minutes. After heating,
the slides were allowed to cool to room temperature and
briefly washed with Tris-buffered saline. Endogenous per-
oxidase activity was blocked with 3% hydrogen peroxide
in methanol for 5 minutes. Normal serum (Novostain
Super ABC kit, Novocastra, Newcastle upon Tyne, UK)
was used for 30 minutes in order to block non-specific
immunoassaying. Immunohistochemical staining was
performed using an avidin-biotin peroxidase system
(Novostain Super ABC kit, Novocastra, UK). The follow-
ing primary antibodies were incubated overnight at room
temperature: ER (1:100, clone 6F11, Novocasta, UK), PR
(1:100, clone 1A6, Novocasta, UK), p21 (1:50, clone
4D10, Novocastra, UK), HER-2 oncoprotein (1:300, clone
CB11, Novocastra, UK), and p53 (1:100, clone DO-7,
Novocastra, UK). Following washes in PBS, biotinylated
universal secondary antibody (Novostain Super ABC kit,
Novocastra, UK) was applied for 30 minutes. The sections
were incubated with the avidin-biotin complex reagent
(Novostain Super ABC kit, Novocastra, UK) for 30 min-
utes and developed with 3.3-diaminobenzidine tetrahy-
drochloride (DAB) in phosphate-buffered saline, pH 7.5,
containing 0.036% hydrogen peroxide for 5 minutes.
Light Mayer's hematoxylin was applied as a counterstain.
The slides were then dehydrated in a series of ethanols
and mounted with Permount (Fischer, Fairlawn, NJ).
Cases of invasive ductal carcinoma, previously known to
be positive for ER, PR, p21, p53 or HER-2, were used as
positive controls. Negative controls for immunostaining
were prepared by omission of the primary antibody.
Scoring methods
The cases were interpreted as positive for p21 if more than
5% of the tumors cells showed nuclear staining [13] and
were considered positive to ER, PR and p53 protein
expression if more than 10% of the tumors cells showed
nuclear staining. HER-2 expression was scored according
to the degree and the proportion of membrane staining
according to HercepTest protocol [14,15]. HER-2 expres-
sion was negative with a score of 0 or 1+. A score of 0 was
defined as no staining or membrane staining in less than
10% of tumor cells. A score 1+ comprised faint or par-
tially-stained membrane in more of 10% of tumor tissue.
Overexpression of HER-2 was scored as 2+ when weak to
moderate complete membrane staining was present in
more than 10% of tumor cells. A score of 3+ was inter-
preted as strong, complete membrane staining in more
than 10% of the tumor.
Study endpoints
The primary goal was to test the correlation among p53,
p21 and HER-2 protein expression and clinical response
to neoadjuvant chemotherapy with docetaxel and epiru-
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bicin combination and to evaluate the impact of immu-
nohistochemical and clinic-pathological parameters in
disease free and overall survivals. A secondary goal was to
study the ability of neoadjuvant taxane and anthracycline
based chemotherapy to change tumor protein expression.
We also studied the association between protein changes
and the impact in disease free and overall survivals. The
third objective was to evaluate the efficacy and toxicity of
a neoadjuvant docetaxel and epirubicin combination. To
test the treatment efficacy, we examined a clinical param-
eter of response and the type of surgery performed.
Statistical analysis
The McNemar test was used to evaluate the paired correla-
tion between p53, p21 and HER-2 protein expression
before and after neoadjuvant chemotherapy. Spearman's
coefficient of rank correlation [16] was used to determine
the correlation between axillary lymph node status and
clinical response and to evaluate the correlation between
clinical response and the risk of death in disease progres-
sion. The relationship between the clinical response with
the patients' characteristics and histopathological patterns
was evaluated with Fisher exact test and chi-squared test.
The relationship between the number of chemotherapy
cycles was analyzed with the Mann-Whitney test. The dis-
ease free survival (DFS) and overall survival (OS) were
analyzed by the Kaplan-Meyer curve. MedCalc version
6.16.000 and Graphpad Prism version 4 software were
used for the above statistical analyses. Multivariate analy-
sis, to test the correlation between HER-2 protein expres-
sion, clinical response, axillary lymph node status and
type of surgery performed with the risk of recurrence and
death to disease progression, was performed using a nom-
inal logistic fit with JMP 6.0 SAS software. The statistical
significance was established as p < 0.05.
Results
Neoadjuvant treatment, clinical response rate and surgery
The objective clinical response (OR) was observed in 46
patients (76.6%) treated with neoadjuvant chemother-
apy. The clinical complete response rate (cCR) was 15%
(nine patients) and the pathological complete response
rate (pCR), defined as the absence of residual invasive car-
cinoma, was 5% (three patients). Patients with stable and
progressive disease were defined as no response patients
(NR). The NR rate was 23.3% (14 patients) and progres-
sive disease was observed in only two patients (3.3%).
Surgery could be performed in fifty-nine patients
(98.3%). One patient with no response to the primary
docetaxel plus epirubicin combination was submitted to
second line chemo-radiation therapy. The tumor was
resistant to second line treatment and she died due to
metastatic disease progression before surgery could be
performed. Breast conserving surgery could be performed
in forty patients (66.7%). Modified Radical Mastectomy
was performed in patients for whom breast-conserving
therapy was not indicated. Patients with OR had a higher
breast conserving surgery rate than patients with NR
(73.9% vs. 35.7%; p = 0.03, chi-square test).
Axillary lymph nodes were assessed histologicaly in 59
patients undergoing axillary node dissection. The median
number of positive lymph nodes in patients with OR was
0 (0 – 19) and in patients with NR was 3 (0 – 25). There
was a positive correlation between the lack of clinical
response and the number of lymph node metastases (p =
0.03; Sperman r). The response to neoadjuvant chemo-
therapy, the type of surgery performed, and the lymph
node status in patients with OR and NR are summarized
in Table 3.
Clinical and histopathological characteristics and their 
relationship with clinical response
We evaluated the association among clinical response,
patients' characteristics (patient's age, menopausal status,
number of chemotherapy cycles and clinical stage), and
histological (histological grade) and immunohistochemi-
cal patterns (ER, PR, p53, p21 and HER-2 protein expres-
sion). The median age in patients with OR was 51.5 years
(range 35 – 67) and in the group of patients NR, the
median age was 47.5 years (p = 0.3, Student t test). In OR
Table 3: Surgery performed in sixty patients with locally advanced breast cancer subjected to neoadjuvant chemotherapy with 
docetaxel and epirubicin combination.
OR N (%) NR N (%) P Test
Clinical Response 46 (76.7) 14 (33.3) - -
Surgery
RS 12 (26) 7 (50)
BCS 34 (74) 6 (42.8)
NS 0 1 (7.2) 0.03 x2
Node
Median (range) 0 (0 – 19) 3 (0 – 25) 0.03 Spearman r
OR = objective response; NR = no response; RS = radical surgery; BCS = breast conserving surgery; NS = not submitted to surgery.
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group, 24 patients (52.1) and in NR group, 8 patients
(57.1%) %) were classified as post menopausal status (p =
0.9; Chi-square test). The median number of chemother-
apy cycles was three in both groups (p = 0.4; Mann-Whit-
ney test) and there was no difference in clinical stage
between the OR and NR groups of patients (p = 0.78; Chi-
square test).
The estrogen receptor was positive in 72.7% of patients
with OR and in 85.7% of NR patients (p = 0.48; Fisher's
exact test) and the progesterone receptor was positive in
44% and 50% of patients with OR and NR, respectively (p
= 0.76, Fisher's exact test). There were no p53, p21 and
HER-2 protein expression differences before chemother-
apy between the OR and NR groups (p = 0.19, p = 1.0 and
p = 0.43; Fisher exact test, respectively). The histological
grade was not able to predict clinical response (p = 0.2;
Chi-square test). Table 4 shows the relationship between
the clinical response and clinical, pathological and immu-
nohistochemical patterns.
Neoadjuvant chemotherapy and p53, p21 and HER-2 
proteins expression change
The expression of p53, p21 and HER-2 proteins was eval-
uated in biopsy specimens from 60 breast cancer patients
before neoadjuvant chemotherapy. Because no or scarce
residual tumor remained after chemotherapy, the evalua-
tion of p53 and p21 protein expression was not possible
in 6 patients specimens and, HER-2 protein expression
was not carried out in 4 of the patient specimens.
Table 4: Clinical and histological features of sixty patients subjected to neoadjuvant chemotherapy with docetaxel plus epirubicin. 
Patients were divided according to clinical response as objective response (OR) and no response (NR) groups.
OR (n) NR (n) P Test
Age
Median (range) 51,5 (35 – 67) 47,5 (29 – 68) 0.3 Student t
≤ 45 anos 12 7
>45 anos 35 7 0.1 Fisher
Menopausal Status
Post 24 8
Pre 22 6 0.9 x2
CT cycle (range) 3 (2 – 5) 3 (2 – 4) 0.4 Mann-Whitney
CS
IIA 8 4
IIB 15 4
IIIA 5 2
IIIB 14 4
IIIC 3 0 0.78 x2
Grade
I 10 6
II 27 5
III 8 3 0.2 x2
ER
Positive 32 12
Negative 12 2 0.48 Fisher
PR
Positive 20 7
Negative 25 7 0.76 Fisher
ER/PR
Positive 16 7
Negative 22 7 0.75 Fisher
P53
Positive 16 2
Negative 30 12 0.19 Fisher
P21
Positive 15 5
Negative 31 9 1 Fisher
HER-2
Positive 10 1
Negative 36 13 0.43 Fisher
OR = objective response; NR = no response; n = number of patients; CT = chemotherapy; CS = clinical staging; Grade = histological grade (Bloom-
Richardson); ER = estrogen receptor; PR = progesterone receptor.
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Positive p53 expression was identified in 18 patients
(30%) before and in 8 patients (14.5%) after neoadjuvant
chemotherapy. There was a significant reduction in p53
protein expression levels after chemotherapy (p = 0.039;
difference 13.2%; McNemar test). The expression of p21
protein was positive in 13 patients (21.6%) before and in
5 patients (9.2%) after neoadjuvant chemotherapy. Neo-
adjuvant chemotherapy reduced p21 protein expression
levels (p = 0.021; difference= 14.81%; McNemar test).
Positive HER-2 protein overexpression was observed in 11
patients (18.3%) before chemotherapy. After neoadjuvant
treatment, the overexpression of HER-2 protein was
observed in seven patients (12.5%). Neoadjuvant chemo-
therapy was not able to change HER-2 protein expression
levels (p = 0.12; McNemar test). Table 5 shows immuno-
histochemical protein expression levels (p53, p21 and
HER-2) before and after neoadjuvant chemotherapy.
P21 protein expression and its relationship with p53 and 
HER-2 protein expression
We analyzed the relationship between p21 expression and
p53 and HER-2 protein expression in pre-chemotherapy
biopsy specimens. In forty patients with p53 negative
tumors, we found 16 patients with p21 positive protein
expression (40%). In patients with positive p53 expres-
sion (n = 16), we identified 4 patients with p21 positive
tumors (25%). The difference was not significant (Fisher's
exact test; p = 0.2).
In eleven patients with HER-2 overexpression, we
observed p21 positive protein expression in four patients
(36.3%) and, in 49 HER-2 negative patients, the p21
expression was positive in sixteen patients (32.6%). There
was no difference in the expression of p21 in such patients
(Fisher's exact test; p = 1.0).
Disease free and overall survival rates
We evaluated the impact of clinical (age, clinical stage,
clinical response, type of surgery), pathological (histolog-
ical grade, axillary lymph node status) and immunohisto-
chemical (ER, PR, p53, p21 and HER-2 protein
expression) features on disease free and overall survival.
We observed an inverse correlation between clinical
response and the risk of death to disease (p = 0.02; Spear-
man r). In a univariate analysis, only Her-2 overexpres-
sion and two other factors related to clinical response
were related to overall survival: the type of surgery (HR =
0.41, 95% IC = 0.12 to 0.96; p = 0.042) and the presence
of extensive (more than six positive lymph nodes) resid-
ual disease in axillary lymph nodes (HR = 0.35, 95% IC =
0.08 to 0.78; p = 0.017).
In a multivariate analysis, only HER-2 overexpression was
a predictive factor of DFS and OS (p = 0.0007 and p =
0.003, respectively). The median time to DFS was 31
months (HR = 0.35, 95% IC = 0.08 to 0.75; p = 0.014) and
the median time to OS was 40 months (HR = 0.33, 95%
IC = 0.06 – 0.75; p = 0.016). Figures 1 and 2 show the Kap-
lan-Meyer curve for DFS and OS according to HER-2 pro-
tein expression, respectively.
Discussion
Neoadjuvant or induction chemotherapy is the current
standard of care in locally advanced breast cancer [17].
Such treatment can reduce tumor volume, leading to less
aggressive surgery and providing favorable local condi-
tions for surgery in inoperable tumors [1,2]. About 80%
of patients achieve a local benefit due to adequate tumor
downstaging, however, the overall survival, when com-
paring neoadjuvant and adjuvant chemotherapy, is not
influenced by the primary cytotoxic therapy [17].
We evaluated the response to neoadjuvant chemotherapy
in 60 locally advanced breast cancer patients. The objec-
tive clinical response rate was 76.6%, with a complete
pathological response in 5% of patients. Breast conserving
therapy was possible in forty patients (66.6%) and in only
one patient could the surgery not be performed due to the
lack of response to neoadjuvant chemotherapy. Other
studies reported a higher complete pathological response
rate ranging from 8% to 10.5%, using similar chemother-
apy scheme [16,18]. However, the breast conserving sur-
gery rate was higher in our study. They reported a breast
conserving surgery rate of 16% and 15%, respectively, in
contrast to the study of Ganem et al who reported a breast
conserving surgery rate of 69% [19]. This discordant result
should be attributed to the enrollment of different
number of patients with primary inoperable tumors
among these studies.
The clinical and pathological response to neoadjuvant
therapy in patients with large breast tumors has been
Table 5: Immunohistochemical patterns before and after neoadjuvant chemotherapy with docetaxel plus epirubicin in sixty breast 
cancer patients.
Pre-chemotherapy N (%) Post-chemotherapy N (%) p Dif. (%)
p53 + 18 (30) 8 (14.5) 0.039 13.2
p21 + 13 (21.6) 5 (9.2) 0.021 14.81
HER-2 + 11 (18.3) 7 (12.5) 0.12 NS
N = number of patients; Dif. = difference between before and after chemotherapy – McNemar test; NS = not significant.
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described as an independent prognostic factor [3,4]. We
observed similar results. In our study, patients who
achieved an objective response had a better prognostic
than patients with stable or progressive disease after
induction chemotherapy. The observation that patients
with extensive lymph node metastasis after neoadjuvant
therapy are more propitious to develop metastatic disease
and die due to disease progression than patients with no
extensive axillary metastasis supports the hypothesis that
residual loco regional disease after neoadjuvant chemo-
therapy is a clinical marker of chemotherapy resistance.
The neoadjuvant therapy, considered to be an in vivo
model to test chemotherapy sensitivity, is helpful to assess
biological tumor behavior and to evaluate chemotherapy
mechanisms of function and its relationship to drug
resistance. In a previous study, we observed that the
induction of apoptosis is an important predictor of
response to chemotherapy in breast cancer and that such
an event is influenced by protein tumor expression pat-
terns [7]. In the present study, we evaluated the correla-
tion among patients' characteristics, immuno-
histochemical expression of hormonal receptors (ER and
PR), p53, p21 and HER-2 protein expression and the clin-
ical and pathological response to a neoadjuvant combina-
tion of docetaxel and epirubicin. No parameter studied
was able to predict response to neoadjuvant chemother-
apy.
Changes in protein expression after neoadjuvant treat-
ment have been reported [20,21]. Such observation sug-
gests that chemotherapy can alter the tumor gene
expression and that this event is a important point in drug
sensitivity [7]. In the present study, we confirmed the
reduction in p53 protein expression, as well in p21 pro-
tein expression, after neoadjuvant chemotherapy. How-
ever, the taxane and anthracycline combination in a
neoadjuvant setting was not able to change HER-2 expres-
sion in patients with locally advanced breast carcinoma.
The HER-2 stable phenotype during neoadjuvant chemo-
therapy was reported by others authors [22,23].
Recent studies have been focused on the role of HER-2 as
a predictive factor of response to neoadjuvant chemother-
apy [24-26]. Zhang F et al and Fernández-Sánchez M et al
could not observe a correlation between HER-2 expres-
sion and the clinical or pathological response to neoadju-
vant chemotherapy in patients with breast carcinoma
treated with 5-fluoruracil, doxorubicin and cyclophos-
phamide combination (FAC). Otherwise, Learn PA et al
demonstrated that the addition of docetaxel to anthracy-
cline-based neoadjuvant chemotherapy improved clinical
response rate in HER-2 positive breast cancer patients. In
our study, the expression of the HER-2 protein was an
independent prognostic factor in multivariate analysis;
however, its expression was not able to predict the clinical
and pathological primary tumor response.
We observed that the median time of disease free and the
overall survival were 30 months and 41 months, respec-
tively, in patients with HER-2 positive tumors. These
patients achieved an overall survival rate of 25% after 48
months in contrast with 70% in patients with HER-2 neg-
ative expression. According to SEER estimation, patients
with clinical stage III and grade 3 breast cancer (T3N1M0),
with negative hormonal receptors subjected to no sys-
temic therapy, have a ten year overall survival rate of
33.5% [27]. This observation leads us to offer alternative
therapy with target agents to block the HER-2 activity for
patients with HER-2 amplification. Recent studies have
demonstrated a promising benefit of chemotherapy and
Kaplan-Meyer curve for OS in sixty patients subjected to neoadjuvant chemothe apy with docetaxel and epirubicin according to HER-2 protein expressionFigu e 2
Kaplan-Meyer curve for OS in sixty patients subjected to 
neoadjuvant chemotherapy with docetaxel and epirubicin 
according to HER-2 protein expression.
Kaplan-Meyer curve for DFS in sixty patients subjected to Neo djuvant chemotherapy with docetaxel and epirubicinacc r ing to HER-2 protein expressionFigu e 1
Kaplan-Meyer curve for DFS in sixty patients subjected to 
Neoadjuvant chemotherapy with docetaxel and epirubicin 
according to HER-2 protein expression.
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immunotherapy (trastuzumab) combination regimens in
a neoadjuvant setting in patients with HER-2 amplifica-
tion breast cancer [28,29].
Conclusion
We have concluded that the clinical response to neoadju-
vant chemotherapy is a relevant prognostic factor in
patients with locally advanced breast cancer treated with a
neoadjuvant docetaxel and epirubicin combination. The
value of biological makers as predictive factor of response
to neoadjuvant therapy is still not clear. Advanced breast
tumors exhibit a polyclonal population and the high
number of genetic dysfunction limits the use of specific
markers in clinical practice. Future directions are going to
be based on multiple gene expression patterns, called
genetic signatures. Recent publications have shown a pos-
itive relationship between a gene expression signature and
a complete pathological response to primary chemother-
apy [30,31].
On the other hand, HER-2 overexpression is the major rel-
evant phenotype in breast cancer progression regardless
the clinical response to neoadjuvant chemotherapy. HER-
2 overexpression in primary tumor is a stable phenotype
during neoadjuvant chemotherapy and is a marker of dis-
tant disease progression and death.
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